MAF Test Launches in the US Through NeoGenomics, Challenging Menopause as the Bisphosphonate Gatekeeper
Inbiomotion has launched its MAF Test® in the US through NeoGenomics Laboratories, aiming to improve the selection of early breast cancer patients who would benefit from adjuvant bisphosphonates. The test identifies MAF gene amplification in tumors, challenging the traditional reliance on menopausal status as the sole determinant for bisphosphonate use. This development seeks to personalize treatment by identifying both patients who would benefit, including premenopausal individuals, and those who may experience harm from the drugs.
235,000 individually held shares are part of a fund manager’s reported NeoGenomics (NEO) stake.
Mathew P. Arens, managing member and majority owner of First Light Asset Management, LLC, has reported a 6.91% beneficial stake in NeoGenomics (NEO), totaling 8,937,280 shares. This includes 235,000 shares held individually with sole control and 264,400 shares in a joint account. First Light Asset Management, LLC itself reports beneficial ownership of 8,437,880 shares, representing 6.52% of the class.
Missed NeoGenomics' Rally? Here's What Buyers Saw
NeoGenomics' stock has seen a 54.9% return over the past year, prompting investors to consider what drove this rally. While a bullish narrative focused on aging populations and digital health tools driving oncology testing suggested a fair value of US$14, a bearish view highlighted margin pressures and regulatory risks. Recent Q3 2026 results showed improved revenue and narrowed losses, supporting the bullish thesis, though profitability remains unproven.
Behavioral Patterns of NEO and Institutional Flows
This report analyzes Neogenomics Inc. (NYSE: NEO), highlighting a near-term strong sentiment influencing a neutral mid-term outlook towards a positive long-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also identifies key support and resistance signals across different time horizons for NEO.
NeoGenomics (NEO) Stock Looks Overvalued Despite Its 68% One Year Run
NeoGenomics (NEO) has seen a 68.3% return over the past year, leading to questions about its current valuation relative to its sales. The article suggests that NeoGenomics appears overvalued based on its P/S ratio of 2.8x compared to the broader Healthcare sector and its peer group, both at 1.3x. Despite this, some analyst narratives suggest the stock is 26% undervalued, citing investments in digital pathology and automation.
NeoGenomics (NEO) Cut Its Losses In Q3, Is The 26% Undervaluation Case Convincing?
NeoGenomics (NEO) reported higher Q3 2026 sales of US$209.25 million and a significantly reduced net loss of US$7.55 million. The stock is currently trading at US$16.84, with a popular narrative suggesting it is 26% undervalued at a fair value of US$22.89, driven by expected operating efficiencies and growth. However, another perspective suggests the stock looks pricey based on a sales multiple (P/S of 2.8x) compared to industry and peer averages, indicating potential multiple risk if sentiment cools.
NeoGenomics (NASDAQ:NEO) Stock Rating Raised to Buy at Wall Street Zen
Wall Street Zen has upgraded NeoGenomics (NASDAQ:NEO) from a "hold" to a "buy" rating, aligning with an overall "Moderate Buy" consensus and an average price target of $20.88 from analysts. The medical research company recently surpassed quarterly earnings and revenue estimates, reporting $0.07 EPS on revenue of $209.25 million, an 11.3% increase year-over-year. Institutional investors hold a significant 98.5% stake in the company, whose shares opened at $16.84.
What NeoGenomics Stock's Narrower Loss Means For Shareholders
NeoGenomics (NEO) reported a narrower loss in Q3 2026, with sales of US$209.25 million and a net loss of US$7.55 million, indicating improved cost discipline. The company's investment narrative focuses on turning rising sales from its oncology testing platform into a profitable network, driven by the uptake of NGS and liquid biopsy services. Analysts project future profitability and significant revenue growth for NeoGenomics by 2029, suggesting a potential upside to its current stock price.
Missed NeoGenomics' Rally? Here Is What Holders Saw
NeoGenomics (NasdaqCM:NEO) saw a 64.4% return for investors over the past year, driven by strong Q3 2026 results, new Medicare coverage for RaDaR ST, and an FDA-approved PTEN diagnostic. The company's revenue increased from US$187.8m to US$209.3m, and its net loss narrowed, supporting a bullish outlook on higher-value oncology assays and improved efficiency. While profitability remains negative, the market's current valuation of US$17.15 reflects a belief in the company's ability to scale new offerings and achieve higher margins through strategic investments.
NeoGenomics, Inc. (NG9.F) Seasonal returns chart
This article presents a seasonal returns chart for NeoGenomics, Inc. (NG9.F), displaying the average monthly price return from 2016 to 2026. As of the current market data, NeoGenomics, Inc. shows a price of 15.10 EUR, up 1.89%. The chart allows users to view seasonality over various periods.
NeoGenomics, Inc. (NG9.F) stock price, news, quote and history
This page provides an overview of NeoGenomics, Inc. (NG9.F) stock, including its current price, market performance, and a compilation of recent news articles. The news highlights NeoGenomics' Q3 earnings, with several reports indicating that the company beat expectations in both earnings and revenues. Key topics in the articles include product mix shifts, margin expansion, and CEO transitions.
How Long Can NeoGenomics Keep Burning Cash?
NeoGenomics (NEO) is consistently burning cash, having spent $20.7 million in the quarter ending September 30, 2026, and demonstrating a growing burn over the last four quarters. While its $139 million in cash and short-term investments could last five years at the average burn rate or seven quarters at the September rate, debt stands at $449 million. Management attributes the recent cash flow to a DOJ settlement, a new revenue cycle management platform, and infrastructure investment, expecting normalization by early 2027.
NeoGenomics, Inc. (NEO) Seasonal Returns Chart
This article from Yahoo Finance presents a seasonal returns chart for NeoGenomics, Inc. (NEO), showing the average monthly price return between 2016 and 2026. As of October 30, NEO's stock price was $17.38, down 3.07%, and further decreased to $17.11 in after-hours trading.
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $23.1, Implies 28% Upside
NeoGenomics, Inc. (NEO) has seen its average 12-month price target increase to $23.1 from $21.95, according to estimates from 10 analysts. This updated target suggests a potential upside of approximately 28% from the October 28 closing price. The consensus rating among 12 covering analysts remains a "Buy," with 9 Buys and 3 Holds.
BTIG reiterates Neogenomics stock Buy rating on strong test growth
BTIG has reiterated a Buy rating and a $28.00 price target for Neogenomics (NASDAQ: NEO) after the company reported strong third-quarter results, including an 11% revenue growth and a 29% year-over-year increase in next-generation sequencing revenue. Analysts predict the company will achieve profitability this year. The company is also expanding its sales force and seeing positive momentum with new commercial payor contracts.
NeoGenomics Reports Third Quarter 2026 Results
NeoGenomics, Inc. announced strong third-quarter 2026 results, with total revenue increasing 11% year-over-year to $209 million and clinical services revenue growing 13%, driven by 29% growth in NGS revenue. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance, reflecting confidence in its strategic execution and operational initiatives. Additionally, NeoGenomics announced a planned leadership succession, with Warren Stone set to become CEO in January 2027.
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $22.4, Implies 25% Upside
NeoGenomics, Inc.'s average price target has been raised by analysts from $21.95 to $23.1, with a potential upside of approximately 28% based on the Oct. 28 closing price. The consensus rating for the stock remains a "Buy" among 12 covering analysts. Investors can explore more price target data and analyst recommendations on TradingView.
NeoGenomics Raises 2026 Guidance as Q3 NGS Revenue Grows 29%
NeoGenomics Inc. has raised its full-year 2026 revenue guidance to $807 million-$809 million and adjusted EBITDA to approximately $60 million, following strong third-quarter performance. The company reported an 11% increase in Q3 revenue to $209 million, driven by 29% growth in next-generation sequencing (NGS) revenue and a shift toward higher-value testing. NeoGenomics also announced a leadership transition, with Warren Stone becoming CEO and Tony Zook transitioning to executive chairman, effective January 4, 2027.
NeoGenomics Raises Full-Year 2026 Guidance on 11 Percent Q3 Revenue Growth
NeoGenomics announced it is raising its full-year 2026 guidance following an 11 percent revenue growth in the third quarter. The company's strong financial performance indicates a positive outlook for the remainder of the fiscal year. This update was reported by Yaakov Zinberg on October 29, 2026.
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $22.8, Implies 27% Upside
NeoGenomics, Inc. (NEO) has seen its average 12-month price target raised from $21.95 to $22.8 by 10 analysts, implying a potential 27% upside from its October 28th closing price. The consensus rating for NEO remains a "Buy" from 12 analysts, with 9 recommending Buy and 3 recommending Hold.
Neogenomics Inc. (NEO) Earnings, Actual EPS, EPS Estimates & Results
Neogenomics Inc. (NEO) reported strong Q3 '26 earnings, exceeding EPS estimates with $0.07 and revenue estimates with $209.25M. The company also raised its full-year 2026 consolidated revenue and adjusted EBITDA guidance, citing significant growth in revenue and NGS. Despite an increase in clinical volume, the company noted risks related to reimbursement, regulation, and supply costs.
NeoGenomics | 10-Q: Quarterly report
This entry indicates that NeoGenomics has filed its quarterly report, known as a 10-Q. This document provides a comprehensive overview of the company's financial performance during the quarter. Investors and analysts use this report to assess the company's health and make informed decisions.
NeoGenomics Q3 2026 Earnings Call Transcript
NeoGenomics reported strong Q3 2026 results with 13% year-over-year clinical revenue growth and 29% NGS revenue growth, leading to increased full-year revenue and adjusted EBITDA guidance. CEO Tony Zook announced his transition to Executive Chair, with Warren Stone becoming CEO in January 2027. The company is focused on expanding NGS and MRD offerings, achieving MolDX coverage for RaDaR immunotherapy treatment response monitoring, and investing in "Lab of the Future" initiatives.
Earnings call transcript: NeoGenomics tops Q3 2026 estimates, lifts outlook
NeoGenomics Inc. (NEO) reported strong third-quarter 2026 results, surpassing Wall Street expectations for both earnings and revenue, driven by robust growth in its precision oncology tests, particularly next-generation sequencing (NGS). The company saw adjusted EPS of $0.07 against a $0.05 forecast and revenue of $209 million compared to an expected $206.6 million, leading to an upward revision of its full-year 2026 guidance for revenue and adjusted EBITDA. Key drivers included 13% growth in clinical testing, a 29% increase in NGS revenue, and an expanded adjusted gross margin of 49%.
NeoGenomics, Inc. Estimates – NASDAQ:NEO
This page provides financial data and analyst estimates for NeoGenomics, Inc. (NASDAQ: NEO), allowing users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time for informed decision-making.
NeoGenomics (NEO) Projected to Announce Earnings on Wednesday
NeoGenomics (NASDAQ:NEO) is anticipated to release its Q3 2026 earnings after the market closes on Wednesday, October 28th. Analysts project earnings of $0.0555 per share and revenue of $206.70 million. The company recently surpassed expectations in its last quarter, reporting $0.05 EPS and $201.66 million in revenue, leading to a "Moderate Buy" consensus rating from analysts with an average price target of $18.17.
Needham raises target for NeoGenomics stock from USD 19.00 to USD 22.00
Needham has increased its price target for NeoGenomics (NEO) stock from USD 19.00 to USD 22.00, maintaining a Buy rating. This new target is 31.50 percent higher than the stock's Nasdaq price of USD 16.73 as of October 20, 2026. NeoGenomics is set to release its third-quarter 2026 results on October 28, 2026.
NeoGenomics, Inc. (NEO) options chain
This article presents the options chain for NeoGenomics, Inc. (NEO) for the expiration date of November 20, 2026. It includes detailed call and put option data such as strike prices, last trade dates, last prices, bid/ask prices, changes, volume, open interest, and implied volatility. The data shows that NeoGenomics, Inc. closed at $16.65 on October 16 and was trading slightly lower in pre-market.
NeoGenomics stock fell 3.48 percent to USD 16.65 on October 16
NeoGenomics (NEO) stock declined by 3.48% to USD 16.65 on October 16, 2026, on Nasdaq, ahead of its Q3 2026 earnings report scheduled for October 28. Needham analysts maintain a Buy rating with a USD 22.00 target, representing a 32.13% upside from the current price. The company's market capitalization stood at USD 2.2 billion, with the stock trading below its 52-week high but significantly above its low.
NeoGenomics, Inc. (NEO) stock price, news, quote and history
NeoGenomics, Inc. (NEO) stock closed at $16.42, down 1.38%, on October 19, 2026. The company, which specializes in cancer-focused testing laboratories, has seen its stock return 39.63% year-to-date and 63.38% over the past year. Analysts have a target estimate of $21.85, with a recent rating of 'Buy' and a price target raise to $20 by StoneX on October 6, 2026.
Needham sets USD 22.00 target for NeoGenomics stock
Needham has raised its price target for NeoGenomics (NEO) to USD 22.00, representing a 28.06% increase from its current Nasdaq quote. NeoGenomics is scheduled to report its third-quarter 2026 financial results on October 28, 2026, which will serve as a near-term test for the new analyst target. The company, which specializes in oncology-focused cancer diagnostics, had a market capitalization of USD 2.2 billion as of October 15, 2026.
NeoGenomics, Inc. (NEO) Stock Forecasts
This article provides a stock forecast for NeoGenomics, Inc. (NEO), a company specializing in oncology diagnostic testing and consultative services. An Argus report from October 14, 2026, is highlighted, noting a current price of $17.25 for NEO. The report offers insights into the company's sector, rating, earnings estimate, and price target, with additional premium content available through an upgrade.
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NeoGenomics has expanded its partnership with Indica Labs to enhance its digital pathology infrastructure and accelerate AI-driven diagnostics. This collaboration will utilize Indica Labs' cloud-based HALO AP platform to integrate various AI tools, supporting emerging AI-based biomarker testing and future co-development efforts. The initiative aims to limit integration costs while advancing AI capabilities in clinical trial collaborations.
NeoGenomics expands Indica Labs partnership for digital pathology
NeoGenomics has expanded its partnership with Indica Labs for a broader digital pathology rollout across its cancer-testing operations, utilizing Indica Labs' cloud-based HALO AP image management platform. The collaboration aims to streamline operations, facilitate AI co-development, and expand curated pathology datasets, though specific financial terms or deployment deadlines were not disclosed. The HALO AP platform is currently for research use only in the United States, but is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland.
NeoGenomics expands Indica Labs partnership for AI pathology By Investing.com
NeoGenomics Inc. announced an expansion of its partnership with Indica Labs to enhance its digital pathology infrastructure, aiming to accelerate AI-driven diagnostics. The oncology diagnostics company will utilize Indica Labs' HALO AP platform, a cloud-based, vendor-neutral image management system, to integrate AI tools and provide digital capabilities to customers. This collaboration seeks to improve workflow efficiency for pathologists and clinicians and support future AI co-development and clinical trial initiatives.
NeoGenomics expands digital pathology deal with Indica Labs
NeoGenomics has expanded its partnership with Indica Labs to enhance its digital pathology infrastructure using AI-driven diagnostic tools. The company will utilize Indica Labs' HALO AP® platform, a cloud-based, vendor-neutral image management system, to integrate AI tools and support future co-development projects and clinical trials. This collaboration aims to provide more efficient workflows for pathologists and clinicians and advance cancer diagnosis and therapy selection.
NeoGenomics to report Q3 2026 results after market close, host webcast and call
NeoGenomics (NEO) announced it will release its third-quarter 2026 financial results after the U.S. market closes on October 28, 2026. The company will also host a management webcast and conference call on the same day at 4:30 p.m. ET to discuss the results. Interested parties can access the replay via ir.neogenomics.com.
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics, Inc. (NASDAQ: NEO) announced it will release its Q3 2026 financial results after the market closes on Wednesday, October 28, 2026. The company will host a webcast and conference call at 4:30 p.m. ET on the same day to discuss the results and recent company highlights. Investors can access the webcast via the company's investor relations website.
(NEO) Price Dynamics and Execution-Aware Positioning
This article provides an in-depth analysis of Neogenomics Inc. (NYSE: NEO), highlighting weak near and mid-term sentiment but a strong long-term positive outlook. It details specific trading strategies generated by AI models, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward setups. The report emphasizes institutional-grade analysis for informed trading decisions.
Form 4 NeoGenomics Inc For: 12 October By Investing.com
This article reports on a Form 4 filing for NeoGenomics Inc. on October 12, 2026. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article provides minimal detail beyond the filing's existence and date.
NeoGenomics, Inc. (NEO) Stock Forecasts
Argus lowered its target price for NeoGenomics, Inc. (NEO) to $17.00. The company provides oncology diagnostic testing and consultative services, including laboratory services and professional interpretation of test results. Investors can upgrade to premium research reports for detailed company profiles and trade insights.
People in the News at 3billion, Quest Diagnostics, Alamar Biosciences, NeoGenomics
This article announces personnel updates at several companies in the precision medicine and diagnostics sector. It mentions news concerning appointments or changes at 3billion, Quest Diagnostics, Alamar Biosciences, and NeoGenomics.
NeoGenomics appointed Warren Stone CEO. NeoGenomics stock fell 1.75 percent
NeoGenomics has appointed Warren Stone as CEO, effective January 4, 2027, which
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
NeoGenomics has announced a planned executive leadership and Board of Directors succession. Warren Stone, current President and COO, will become CEO and join the Board on January 4, 2027, succeeding Tony Zook, who will transition to Executive Chairman. The company also expects preliminary unaudited third-quarter revenue of approximately $209 million, with NGS revenue growth of about 28%, leading to an anticipated increase in full-year total revenue guidance.
NeoGenomics picks Warren Stone to lead company in Fort Myers
NeoGenomics Inc., a Fort Myers-based cancer diagnostics company, has appointed Warren Stone as its new CEO. Stone, currently the company's president and COO, will take over the role and join the board on January 4, 2027. This leadership change is part of a planned succession strategy for the company.
NeoGenomics on 'More Solid Footing' With Strong Revenue Growth, Needham Says
Needham & Co. reiterated a Buy rating on NeoGenomics and adjusted its price target from $19 to $22, citing strong revenue growth that puts the company on "more solid footing." The report highlights a positive outlook for the cancer diagnostics company, which recently announced new CEO and board changes, and has seen expanded Medicare coverage for its RaDaR ST assay.
NeoGenomics (NEO) withheld 6,911 shares for taxes as its COO acquired 17,562 shares.
NeoGenomics Inc.'s President and COO, Warren Stone, exercised 17,562 restricted stock units on October 1, 2026, acquiring an equal number of common shares. The company withheld 6,911 common shares to cover tax obligations associated with this transaction. The filing details various other stock options and performance stock units held by Stone, with different vesting schedules and expiration dates.
What's Going On With NeoGenomics Stock Tuesday?
NeoGenomics Inc. announced an executive succession plan and preliminary Q3 2026 financial results, which caused its stock to drop over 12%. Warren Stone will become CEO, and Tony Zook will transition to executive chair, effective January 4, 2027. The company expects Q3 revenue of approximately $209 million and reiterated its 2026 revenue guidance.
What's Going On With NeoGenomics Stock Tuesday?
NeoGenomics Inc. (NASDAQ: NEO) announced an executive succession plan, with Warren Stone to become CEO, and released preliminary third-quarter revenue of $209 million. Following these announcements, the stock fell over 12%. Analysts from William Blair reiterated a Market Perform rating, citing valuation concerns despite growth potential, while BTIG upgraded the stock to Buy and Needham maintained its Buy rating with an increased price target.
NEOGENOMICS, INC. : NEEDHAM RAISES TARGET PRICE TO $22 FROM $19
Needham has raised its target price for NEOGENOMICS, INC. (NEO.O) from $19 to $22. This update reflects an analyst's revised outlook on the company's stock. The article, provided by Reuters, highlights this specific financial adjustment for Neogenomics.